Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK4424989
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK4424989 is an investigational **four-component prophylactic vaccine** developed by GSK to prevent infections caused by *Streptococcus pyogenes* (group A streptococcus, Strep A). The recombinant protein and glycoconjugate vaccine is designed to induce antibody responses against four Strep A antigens: streptolysin O, *S. pyogenes* cell envelope protease, *S. pyogenes* adhesion and division protein, and group A carbohydrate. It is being evaluated in a randomized, placebo-controlled Phase 1 study in healthy adults aged 18–25 years, using formulations adjuvanted with aluminum hydroxide or AS37.
- Other names
- GSK 4-component Strep A vaccineGSK4-component Strep A vaccineGSK-4-component Strep A vaccine4-component vaccine against Group A Streptococcus pyogenes
02
Targets
SLO (Streptolysin O)GAC (Group A carbohydrate antigen)SpyCEP (Streptococcus pyogenes cell envelope protease)
Beyond the preview
Go deeper on GSK4424989.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK4424989.